Novo Nordisk NVO announced that it has received a complete response letter from the FDA for its biologics license application (“BLA”) for once-weekly basal insulin icodec. The BLA seeks approval for once-weekly basal insulin icodec for the treatment of diabetes mellitus. The application was submitted in April 2023. The FDA requested information related to the manufacturing process and the type 1 diabetes indication before it can complete the review of the application. Novo is evaluating the content of the CRL and will work closely with the FDA to fulfill the requests. An FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting was convened in May 2024 with a panel of independent scientific experts to discuss the benefit-risk of once-weekly basal insulin icodec in type 1 diabetes. The panel determined that the data available were not sufficient to conclude on a positive benefit-risk in type 1 diabetes. The Advisory Committee did not discuss the use of once-weekly insulin icodec in type 2 diabetes. Please note that insulin icodec is already approved under the brand name Awiqli in the EU, Canada, Australia, Japan and Switzerland for the treatment of both type 1 and type 2 diabetes and in China for type 2 diabetes. Year to date, shares of NVO have jumped 38% compared with the industry’s 21.8% growth. Zacks Investment Research Image Source: Zacks Investment Research The stupendous performance that the stock was witnessing earlier on in the year due to exemplary growth of its obesity drug Wegovy (semaglutide) has somewhat been offset by a few setbacks in recent times. Semaglutide is marketed as Wegovy and Ozempic for obesity and diabetes, respectively. Earlier in the week, data from a new study showed that patients who received Eli Lilly’s LLY obesity drug Mounjaro (tirzepatide) significantly lost more weight than those who received Wegovy. While both medications were shown to be effective in achieving weight loss, findings indicate that Mounjaro may be more beneficial. After three months, patients taking the Lilly drug lost an average of 5.9% of their body weight compared with 3.6% for those on Wegovy. This trend also continued at six and 12 months, with Mounjaro users achieving an average weight loss of 10.1% and 15.3%, respectively, versus 5.8% and 8.3% for Wegovy users. The data also showed that patients taking Lilly’s drug were more likely to reach weight loss milestones. Last week, shares of both NVO and LLY slipped after a study showed that patients who received Novo semaglutide could develop a rare blinding eye disorder. The study, which investigators led from a Harvard-affiliated teaching hospital, showed that patients who were prescribed semaglutide were at a higher risk of developing non-arteritic anterior ischemic optic neuropathy than those taking other diabetes or weight loss drugs. This condition restricts blood flow to the optic nerve and can cause permanent blindness. Shares of both companies took a beating after President Joe Biden and Senator Bernie Sanders called out Novo and Eli Lilly for the ‘unconscionably high’ prices of their weight-loss drugs. Zacks Rank and Stocks to Consider Novo currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector are Entrada Therapeutics TRDA and Corcept Therapeutics CORT, both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Entrada’s loss per share estimate for 2024 has narrowed from 27 cents to 13 cents in the past 60 days. The same for 2025 has narrowed from $3.44 to $3.21 in the past 30 days. In the past 60 days, estimates for CORT’s 2024 earnings per share have improved from 90 to 95 cents. Shares of CORT have rallied 24.5% in the past three months. CORT’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 33.7%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO):Free Stock Analysis Report Eli Lilly and Company (LLY):Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT):Free Stock Analysis Report Entrada Therapeutics, Inc. (TRDA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...